Current non-surgical measures of breast cancer prevention using tamoxifen or aromatase inhibitors rely on evidence gained from adjuvant treatment and offer poor protection against the triple-negative subtype typically associated with the BRCA1 mutation carrier state [1,2]. This evidence concerns the gene BRCA1 and breast carcinoma.